Enhanced primary hemostasis is thought to be secondary to increased presence of higher molecular weight VWF, higher concentrations of VWF, higher hematocrit, and larger red blood cell mean ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Viela Bio today announced that N-MOmentum, a pivotal trial of inebilizumab, met its primary and key secondary endpoints in patients with neuromyelitis optica ...